Alexo starts dosing in Phase I trial of ALX148 to treat solid tumours and lymphoma

Immuno-oncology company Alexo Therapeutics has started dosing patients in the Phase I clinical trial of a fusion protein ALX148 for the treatment of solid tumours and lymphoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news